Maria Fardis's most recent trade in CRISPR Therapeutics AG was a trade of 13,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Maria Fardis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Maria Fardis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Maria Fardis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Maria Fardis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 250,000 | 250,000 | - | - | Stock Option (right to buy) |